Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00994318 · ClinicalTrials.gov registry record · Phase 3
Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)
A Phase 3 study, sponsored by Vifor Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 626
- Enrollment target
NCT00994318 is a Phase 3 study that has completed, run by Vifor Pharma. The registered enrollment target is 626 participants.
The verdict
NCT00994318, a Phase 3 study, has completed, sponsored by Vifor Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 626 participants
- Enrollment target
Study Summary
Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
Interventions
- DRUG FCM (Ferric carboxymaltose) high ferritin target
- DRUG FCM (Ferric carboxymaltose) low ferritin target
- DRUG Oral Iron (Ferrous sulphate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 626 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00994318
The ClinicalTrials.gov registry entry for NCT00994318 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 626 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vifor Pharma, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which FCM (Ferric carboxymaltose) high ferritin target is the first listed.
NCT00994318 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00994318 about?
NCT00994318 is a clinical study titled "Ferric Carboxymaltose (FCM) Assessment in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)". Phase IIIb study to evaluate the long-term efficacy of ferric carboxymaltose (FCM) (using targeted ferritin levels to determine dosing) or oral iron in non-dialysis-dependent chronic kidney disease (NDD-CKD) subjects with iron deficiency anaemia (IDA).
What is the current status of trial NCT00994318?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 626 participants. The study started on 2009-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00994318?
The interventions under investigation include: FCM (Ferric carboxymaltose) high ferritin target (DRUG), FCM (Ferric carboxymaltose) low ferritin target (DRUG), Oral Iron (Ferrous sulphate) (DRUG).
Who is sponsoring clinical trial NCT00994318?
This trial is sponsored by Vifor Pharma, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.